Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI), but limited data exist on the efficacy of Len +/- Eve after progression on immune checkpoint inhibitors (ICI) and VEGFR-TKI.